Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that 12-month data from its real-world study in Europe evaluating Sebacia Microparticles for treatment of facial acne will be presented during the American Academy of Dermatology (AAD) 2019 Annual Meeting, being held March 1-5 in Washington, D.C. at the Walter E. Washington Convention Center.

Read More